Characteristics of diffuse large Bcell lymphoma in Chinese populations

doi:10.3760/cma.j.issn.1673-422X.2018.03.014

Abstract

Abstract: Diffuse large Bcell lymphoma (DLBCL) is the most common type of nonHodgkin lymphoma. Generally, it can be divided into two immunological subgroups: germinal center Bcelllike (GCB) and nongerminal center Bcelllike (nonGCB), and they are different both in distribution and prognosis in different populations. And DLBCL has unique genetic characteristics in Chinese populations. With the global advances in personalized medicine, people gradually realize that only personalized therapy could be obtain maximal therapeutic effect for different populations, especially person from different kind of ethnic group.

Key words: Lymphoma,Bcell, Ethnic groups, Genetic heterogeneity

Zhang Qian, Duan Shan. Characteristics of diffuse large Bcell lymphoma in Chinese populations[J]. Journal of International Oncology, 2018, 45(3): 187-190.

References

［1］ Georgiou K, Chen L, Berglund M, et al. Genetic basis of PDL1 overexpression in diffuse large Bcell lymphomas［J］. Blood, 2016, 127(24): 3026-3034. DOI: 10.1182/blood-2015-12-686550. ［2］王钰乔, 沈霞, 李中林, 等. 原发性中枢神经系统淋巴瘤影像学及病理学特征临床研究［J］. 中国现代神经疾病杂志, 2016, 16(11): 797-802. DOI: 10.3969/j.issn.1672-6731.2016.11.014. ［3］ Xu PP, Zhong HJ, Huang YH, et al. Bcell function gene mutations in diffuse large Bcell lymphoma: a retrospective cohort study［J］. EBioMedicine, 2017, 16: 106-114. DOI: 10.1016/j.ebiom.2017.01.027. ［4］ Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms［J］. Blood, 2016, 127(20): 2375-2390. DOI: 10.1182/blood2016-01-643569. ［5］ ColonOtero G, Van Wier SA, Ahmann GJ, et al. Prevalence of BCL2/J(H) translocation in healthy African Americans［J］. Ann Hematol, 2017, 96(1): 51-55. DOI: 10.1007/s00277-016-2842-4. ［6］ Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large Bcell lymphoma by immunohistochemistry using a tissue microarray［J］. Blood, 2004, 103(1): 275-282. DOI: 10.1182/blood-2003-05-1545. ［7］ Choi WW, Weisenburger DD, Greiner TC, et al. A new immunostain algorithm classifies diffuse large Bcell lymphoma into molecular subtypes with high accuracy［J］. Clin Cancer Res, 2009, 15(17): 5494-5502. DOI: 10.1158/1078-0432.CCR-09-0113. ［8］李小秋, 李甘地, 高子芬, 等. 中国淋巴瘤亚型分布: 国内多中心性病例10002例分析［J］. 诊断学理论与实践, 2012, 11(2): 111-115. DOI: 10.3969/j.issn.1671-2870.2012.02.006. ［9］赵伟, 陈铜兵, 谈炎, 等. 弥漫性大B细胞淋巴瘤的临床特征和免疫表型人群分布［J］. 江苏医药, 2013, 39(7): 849-850. ［10］ Shiozawa E, YamochiOnizuka T, Takimoto M, et al. The GCB subtype of diffuse large Bcell lymphoma is less frequent in Asian countries［J］. Leuk Res, 2007, 31(11): 1579-1583. DOI: 10.1016/j.leukres.2007.03.2017. ［11］ Chen YW, Hu XT, Liang AC, et al. High BCL6 expression predicts better prognosis, independent of BCL6 translocation status, translocation partner, or BCL6deregulating mutations, in gastric lymphoma［J］. Blood, 2006, 108(7): 23732383. DOI: 10.1182/blood200605022517. ［12］ Oh YH, Park CK. Prognostic evaluation of nodal diffuse large B cell lymphoma by immunohistochemical profiles with emphasis on CD138 expression as a poor prognostic factor［J］. J Korean Med Sci, 2006, 21(3): 397-405. DOI: 10.3346/jkms.2006.21.3.397. ［13］陈燕. 中国人弥漫性大 B 细胞淋巴瘤免疫学亚型, 遗传学异常和BCL2蛋白表达机制的研究［D］. 上海: 复旦大学, 2009. ［14］ Fisher RI, Gaynor ER, Dahlberg S, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced nonHodgkin′s lymphoma［J］. N Engl J Med, 1993, 328(14): 1002-1006. DOI: 10.1056/NEJM199304083281404. ［15］ Habermann TM, Weller EA, Morrison VA, et al. RituximabCHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large Bcell lymphoma［J］. J Clin Oncol, 2006, 24(19): 3121-3127. DOI: 10.1200/JCO.2005.05.1003. ［16］ Huang Y, Ye S, Cao Y, et al. Outcome of RCHOP or CHOP regimen for germinal center and nongerminal center subtypes of diffuse large Bcell lymphoma of Chinese patients［J］. ScientificWorldJournal, 2012, 2012: 897178. DOI: 10.1100/2012/897178. ［17］ Lenz G, Wright G, Dave S, et al. Stromal gene signatures in largeBcell lymphomas［J］. N Engl J Med, 2008, 359(22): 2313-2323. DOI: 10.1056/NEJMoa0802885. ［18］熊佑祯. RCHOP方案应用于成年男女 DLBCL 患者的疗效比较［D］. 济南: 山东大学, 2015. ［19］黄文涛. 弥漫大B细胞淋巴瘤全基因表达谱分析及临床病理研究［D］. 上海: 复旦大学, 2010. ［20］ Yellu M, Guha G, Deeb A, et al. Gender specific mortality in diffuse large B cell lymphoma patients receiving RCHOP［J］. J Clin Oncol, 2015, 33(15 Suppl): e19523. DOI: 10.1200/jco.2015.33.15_suppl.e19523. ［21］ Beheshti A, Neuberg D, Mcdonald JT, et al. The impact of age and sex in DLBCL: systems biology analyses identify distinct molecular changes and signaling networks［J］. Cancer Inform, 2015, 14: 141148. DOI: 10.4137/CIN.S34144. ［22］ Srour L, Zheng YY, Gerrie AS, et al. EFS24 as a predictor of outcome in a populationbased cohort of patients with DLBCL in British Columbia (BC)［J］. J Clin Oncol, 2016, 34(15 Suppl): 7569. DOI: 10.1200/JCO.2016.34.15_suppl.7569. ［23］傅志英, 朱军, 宋玉琴, 等. 525例弥漫大B细胞淋巴瘤预后影响因素分析［J］. 北京大学学报(医学版), 2014, 46(3): 405-411. DOI: 10.3969/j.issn.1671-167X.2014.03.013. ［24］ Gurbaxani S, Anastasi J, Hyjek E. Diffuse large Bcell lymphoma—more than a diffuse collection of large B cells: an entity in search of a meaningful classification［J］. Arch Pathol Lab Med, 2009, 133(7): 1121-1134. DOI: 10.1043/1543-2165-133.7.1121. ［25］ Huang JZ, Sanger WG, Greiner TC, et al. The t(14;18) defines a unique subset of diffuse large Bcell lymphoma with a germinal center Bcell gene expression profile［J］. Blood, 2002, 99(7): 2285-2290. DOI: 10.1182/blood.v99.7.2285. ［26］ Weitmann K, Hirt C, Schwarz S, et al. Influence of reproductive history and exogenous hormone use on prevalence and frequency of circulating t(14;18)positive cells in a populationbased crosssectional study［J］. Cancer Causes Control, 2015, 26(3): 455-465. DOI: 10.1007/s10552-015-0525-4. ［27］ de Miranda NF, Georgiou K, Chen L, et al. Exome sequencing reveals novel mutation targets in diffuse large Bcell lymphomas derived from Chinese patients［J］. Blood, 2014, 124(16): 2544-2553. DOI: 10.1182/blood2013-12-546309. ［28］ Bassig BA, Cerhan JR, Au WY, et al. Genetic susceptibility to diffuse large Bcell lymphoma in a pooled study of three Eastern Asian populations［J］. Eur J Haematol, 2015, 95(5): 442-448. DOI: 10.1111/ejh.12513. ［29］ Yang C, Wang W, Zi Y, et al. Association between tumor necrosis factorα gene polymorphisms and diffuse large Bcell lymphoma in Chinese Han population: evidence from two center casecontrol study and a metaanalysis［J］. Int J Clin Exp Pathol, 2015, 8(10): 13011-13022. DOI: 10.1038/bmt.2017.144. ［30］ Ye X, Zhao K, Wu C, et al. Associations between genetic variants in immunoregulatory genes and risk of nonHodgkin lymphoma in a Chinese population［J］. Oncotarget, 2017, 8(6): 10450-10457. DOI: 10.18632/oncotarget.14426.

[1]	Tao Hengmin, Wei Yumei, Qian Ming. Clinical application of tumor heterogeneity based on MRI texture analysis [J]. Journal of International Oncology, 2017, 44(8): 597-600.
[2]	Yang Qifan, Liu Yangyang, Zeng Yulan, Liu Yuting, Liu Li. Mechanism, detection and clinical implication of tumor heterogeneity [J]. Journal of International Oncology, 2017, 44(12): 922-925.
[3]	KONG Mian, LIN Yu, WANG Jun-Ye, et al. Separation of breast cancer stem cell and its heterogeneity [J]. Journal of International Oncology, 2013, 40(8): 674-677.